Sartorius meets financial targets in 2012

Sartorius has published its financial report for the 2012 full-year period, during which it was able to meet its growth targets and achieve record revenues and earnings.

The life science company's consolidated sales revenue came to 845.7 million euros (722.15 million pounds) during the last fiscal year, up by 15.4 percent year over year, with the 2011 acquisition of Biohit's liquid handling business playing a key role in this growth.

Its bioprocess solutions, lab products and services and industrial weighing divisions all experienced positive momentum, meaning Sartorius slightly outperformed financial targets that had already been raised twice during 2012.

The company's Sartorius Stedim Biotech business unit also experienced new highs in earnings and revenue during the year.

In 2013, the group expects to achieve constant currency sales growth of between six and nine percent  over the 12 months.

Dr Joachim Kreuzburg, chief executive officer of Sartorius, said: "Our considerable growth has enabled us to increase our bottom-line earnings more strongly than expected at the outset of the year and to further lift our profit margin."